fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Tenofovir alafenamide

All products: Limited Use (codes 517, 518, 519, 520, 521)

Vemlidy · DIN 02464241 · 25 mg · tablet

Limited Use, Reason for Use code 517, 518, 519, 520, 521 requiredMarketed · checked November 17, 2026
StatusLimited Use, Reason for Use code 517, 518, 519, 520, 521 required
Write on scriptone applicable Reason for Use code, 517 or 518 or 519 or 520 or 521 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 517, 518, 519, 520, 521
Reason for Use code 517 Confirmed chronic Hepatitis B infection in persons with - HBV DNA greater than or equal to 1000 IU/mL AND - ALT levels greater than ULN OR - Evidence of fibrosis OR - Documented evidence of cirrhosis Coverage limit: LU Authorization Period: 1 year Reason for Use code 518 For patients with chronic Hepatitis B infection who have a contraindication, intolerance or inadequate response to one or more of the following: lamivudine, entecavir, adefovir or telbivudine. Coverage limit: LU Authorization Period: 1 year Reason for Use code 519 Patient is pregnant (2nd trimester or later) with HBV DNA greater than 1,000,000 IU/mL. Coverage limit: LU Authorization Period: 1 year Reason for Use code 520 Patients with chronic Hepatitis B infection currently receiving treatment with tenofovir and requires treatment continuation. Coverage limit: LU Authorization Period: 1 year Reason for Use code 521 Patients with chronic Hepatitis B infection who are scheduled to undergo chemotherapy or significant immunosuppressive treatment. Coverage limit: LU Authorization Period: 1 year
No interchangeable product listed in the Ontario extract
Vemlidy · DIN 02464241 Manufacturer: Gilead Sciences Canada, Inc.; listing date 2026-01-30 Health Canada: Marketed since 2017-06-20 · brand VEMLIDY · ATC J05AF13 TENOFOVIR ALAFENAMIDE · form Tablet · route Oral · ingredients TENOFOVIR ALAFENAMIDE (TENOFOVIR ALAFENAMIDE HEMIFUMARATE) 25 MG · company Gilead sciences canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Vemlidy: Formulary list price $19.55 per unit (the source does not state the unit; exact figure $19.5537). What the ministry pays, not the patient.

Ministry pays: $19.5537 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02464241)

Source record
DIN 02464241: Vemlidy Raw flags: sec12=Y, sec3=Y Item: 081800422; group id 112; item number 0194; lccId 00425; manufacturer id GIL Source form: Tab; strength: 25mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $19.5537; ministry $19.5537 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02464241 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95241
Shortage status: not checked (no credentials)

Other products in the same Health Canada class (J05AF): coverage varies; not interchangeable

  • Abacavir (Ziagen): general benefit
  • Lamivudine (3tc): general benefit, limited Use 502, 503, 504, not a benefit
  • Entecavir (Baraclude): limited Use 505, 506, 507, 508
  • Tenofovir disoproxil (Viread): limited Use 517, 518, 519, 520, 521, 522
  • Adefovir dipivoxil (Hepsera): not a benefit
  • Zidovudine (Retrovir): not a benefit

48 more in the class list below

Other drugs in the same formulary class (08:18 Antivirals) and how they are covered

Matched class: 08:18 Antivirals

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ABACAVIR & LAMIVUDINE & ZIDOVUDINE, ABACAVIR SULFATE, ABACAVIR SULFATE & LAMIVUDINE, BICTEGRAVIR SODIUM/EMTRICITABINE/TENOFOVIR ALAFENAMIDE HEMIFUMARATE, CABOTEGRAVIR, CABOTEGRAVIR & RILPIVIRINE, COBICISTAT & ELVITEGRAVIR & EMTRICITABINE & TENOFOVIR DISOPROXIL FUMARATE, DARUNAVIR & COBICISTAT, DARUNAVIR & COBICISTAT & EMTRICITABINE & TENOFOVIR ALAFENAMIDE, DELAVIRDINE MESYLATE, DOLUTEGRAVIR, DOLUTEGRAVIR & ABACAVIR & LAMIVUDINE, DOLUTEGRAVIR & RILPIVIRINE, DOLUTEGRAVIR SODIUM/LAMIVUDINE, DORAVIRINE, DORAVIRINE/LAMIVUDINE/TENOFOVIR DISOPROXIL FUMARATE, EFAVIRENZ/TENOFOVIR DISOPROXIL FUMARATE/EMTRICITABINE, ELVITEGRAVIR & COBICISTAT & EMTRICITABINE & TENOFOVIR ALAFENAMIDE, EMTRICITABINE & RILPIVIRINE HCL & TENOFOVIR ALAFENAMIDE HEMIFUMARATE, EMTRICITABINE & RILPIVIRINE HCL & TENOFOVIR DISOPROXIL, EMTRICITABINE & TENOFOVIR DISOPROXIL FUMARATE, ETRAVIRINE, FOSAMPRENAVIR CALCIUM, GANCICLOVIR SODIUM, LAMIVUDINE & ZIDOVUDINE, LOPINAVIR & RITONAVIR, MARAVIROC, NELFINAVIR MESYLATE, RALTEGRAVIR POTASSIUM, RILPIVIRINE HYDROCHLORIDE, RITONAVIR Some products covered without a code (check the product listing): ACYCLOVIR, ATAZANAVIR SULFATE, DARUNAVIR, EFAVIRENZ, LAMIVUDINE, NEVIRAPINE, VALACYCLOVIR 08:18 Antivirals

ABACAVIR SULFATE

· 4 products · General benefit · strengths: 20mg/mL, 300mg · O/L, Tab

LAMIVUDINE

· 10 products · General benefit (7), Listed, not a benefit (1), Limited Use, codes 502, 503, 504 (2) · strengths: 10mg/mL, 100mg, 150mg, 300mg · O/L, Tab

ENTECAVIR

· 8 products · Limited Use, codes 505, 506, 507, 508 · strengths: 0.5mg · Tab

TENOFOVIR DISOPROXIL

· 11 products · Limited Use, codes 517, 518, 519, 520, 521, 522 · strengths: 300mg · Tab

ADEFOVIR DIPIVOXIL

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 10mg · Tab

ZIDOVUDINE

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 100mg · Cap

ABACAVIR & LAMIVUDINE & ZIDOVUDINE

· 2 products · General benefit · strengths: 300mg & 150mg & 300mg · Tab

ABACAVIR SULFATE & LAMIVUDINE

· 7 products · General benefit · strengths: 600mg & 300mg · Tab

ACYCLOVIR

· 15 products · Listed, not a benefit (2), General benefit (13) · strengths: 200mg, 400mg, 800mg · Tab

ATAZANAVIR SULFATE

· 12 products · General benefit (8), Off-Formulary Interchangeable, not an ODB benefit (4) · strengths: 150mg, 200mg, 300mg · Cap

BICTEGRAVIR SODIUM/EMTRICITABINE/TENOFOVIR ALAFENAMIDE HEMIFUMARATE

· 1 products · General benefit · strengths: 50mg & 200mg & 25mg · Tab

CABOTEGRAVIR

· 3 products · General benefit · strengths: 200mg/mL, 30mg · Inj Sol-ER Susp 3mL Vial Kit Pk, Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 08:18 and 42 more
Full class listing Related classes: 08:08 Anthelmintics, 08:12 Antibiotics, 08:14 Antifungals, 08:16 Antitubercular Agents, 08:20 Plasmodicides (Antimalarials), 08:24 Sulfonamides, 08:30 Antiprotozoals, 08:32 Trichomonacides, 08:36 Urinary Anti-Infectives, 08:40 Miscellaneous Anti-Infectives Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE VEMLIDY is indicated for the treatment of chronic hepatitis B in adults with compensated liver disease (see WARNINGS AND PRECAUTIONS). Geriatrics (≥ 65 years of age) Clinical trials of VEMLIDY did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients (see ACTION AND CLINICAL PHARMACOLOGY). Pediatrics (< 18 years of age) Safety and effectiveness of VEMLIDY in pediatric patients less than 18 years of age have not been established. https://pdf.hres.ca/dpd_pm/00058101.PDF PM date: August 20, 2020 Source product: VEMLIDY; DIN 02464241; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.